Discover
ACHV
Achieve Life Sciences, Inc.
6.40
2 x 5.07
2 x 8.26
bid
ask
-
0.13
1.99%
2 @ 07:00 AM
6.50 +0.10 (1.56%)
| Ytd | 28.77% | |
| 1y | 188.29% |
6.27
day range
7.11
2.02
52 week range
7.11
| Open | 6.49 | Prev Close | 6.53 | Low | 6.27 | High | 7.11 | Mkt Cap | 657.02M |
| Vol | 3.84M | Avg Vol | 1.93M | EPS | -1.07 | P/E | N/A | Forward P/E | -3.30 |
| Beta | 1.58 | Short Ratio | 23.98 | Inst. Own | 59.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.09 | 200-d Avg | 4.44 | 1yr Est | 16.44 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.26 | -0.36 | -0.1 | -38.46% |
| 2024-08-13 | 2024-06 | -0.22 | -0.25 | -0.03 | -13.64% |
| 2024-05-09 | 2024-03 | -0.24 | -0.26 | -0.02 | -8.33% |
| 2024-03-28 | 2023-12 | -0.32 | -0.26 | 0.06 | 18.75% |
| 2023-11-09 | 2023-09 | -0.34 | -0.34 | N/A | N/A |
| 2023-08-14 | 2023-06 | -0.41 | -0.43 | -0.02 | -4.88% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-14 | Rodman & Renshaw | Upgrade | Buy | |
| 2024-08-15 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-05-13 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-04-17 | JonesTrading | Upgrade | Buy | |
| 2024-04-01 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-03-05 | Lake Street | Upgrade | Buy | Buy |
Profile
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2019-06-10 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2020-08-17 | BENCICH JOHN A | Chief Operating Officer | 141.00 | Conversion of Exercise of derivative security |
| 2020-08-17 | JACOBS CINDY A | Officer | 176.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Franklin Resources, Inc. | 3.87M | 14.67M | 11.26% |
| 2024-09-29 | Propel Bio Management, LLC | 2.45M | 9.30M | 7.13% |
| 2024-09-29 | Blackrock Inc. | 2.07M | 7.85M | 6.02% |
| 2024-09-29 | Vanguard Group Inc | 1.94M | 7.35M | 5.64% |
| 2024-09-29 | Sofinnova Investments, Inc. | 1.51M | 5.74M | 4.40% |
| 2024-09-29 | Geode Capital Management, LLC | 749.11K | 2.84M | 2.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 2.18M | 8.27M | 6.34% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.03M | 3.90M | 2.99% |
| 2024-10-30 | iShares Russell 2000 ETF | 831.63K | 3.15M | 2.42% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 629.87K | 2.39M | 1.83% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 347.96K | 1.32M | 1.01% |
| 2024-09-29 | Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 217.85K | 825.63K | 0.63% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2020-07-31 |
| 1 : 10 | 2018-05-24 |
| 1 : 11 | 2017-08-03 |
| 0.05556 : 1 | 2008-08-21 |